Severity of BA.2 variant and vaccine effectiveness against symptomatic disease in Scotland

Steven Kerr, Chris Robertson, Sam Hillman, Zoe Grange, Christopher Sullivan, Aziz Sheikh

Research output: Contribution to journalLetterpeer-review

Abstract

The first confirmed case of SARS-CoV-2 omicron BA.2 was identified in Scotland on December 23, 2021.1 BA.2 was the dominant variant in Scotland, replacing omicron BA.1.1.529 (BA.1) and accounting for >90% of new cases as of March 23, 2022 (Fig. S1, Supplementary Appendix).1 Initial research suggested that BA.2 was associated with an increase in the odds ratio of infection for both unvaccinated and fully vaccinated individuals compared to BA.1.2 Since then, other studies from Qatar haveshownthatvaccinationcanprovideprotectionagainst symptomatic BA.1 and BA.2 infection,3 but vaccination effectiveness is stronger after a third ‘booster’ dose. We undertook a test-negative design (TND) study of all individuals over the age of 18in Scotland whohadaRT-PCR test for SARS-CoV-2 from the community, were symptomatic at time of test, had their sample virally sequenced between November 1, 2021 and March 20, 2022, and did not have a record of a previous positive test using the Early Pandemic Evaluation and Enhanced Surveillance (EAVE II) platform.
Original languageEnglish
Article number100533
Number of pages3
JournalThe Lancet Regional Health - Europe
Volume23
Early online date4 Nov 2022
DOIs
Publication statusPublished - 31 Dec 2022

Keywords

  • COVID-19
  • BA.2 variant
  • Scotland

Fingerprint

Dive into the research topics of 'Severity of BA.2 variant and vaccine effectiveness against symptomatic disease in Scotland'. Together they form a unique fingerprint.

Cite this